Literature DB >> 2402498

Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.

A Ashkenazi1, L G Presta, S A Marsters, T R Camerato, K A Rosenthal, B M Fendly, D J Capon.   

Abstract

Infection of mononuclear cells by human immunodeficiency virus (HIV) begins with binding of the viral envelope glycoprotein, gp120, to its receptor, CD4. CD4 contains four extracellular immunoglobulin-like domains, the first of which (V1) is sufficient for HIV binding. V1 contains three sequences homologous to the antigen-complementarity-determining regions (CDR1 to -3) of immunoglobulin variable domains. While all three immunoglobulin CDRs are involved in antigen binding, only amino acids within and flanking the CDR2-like region of CD4 have been shown previously to be involved in gp120 binding. To investigate whether other regions in V1 take part in gp120 binding, we substituted alanine for each of 64 amino acids, including all of the hydrophilic residues in this domain. Mutations at four locations outside the CDR2-like sequence (amino acids 29, 59-64, 77-81, and 85) markedly affected gp120 binding, but not the overall structure of V1 as probed with eight conformationally sensitive monoclonal antibodies. Thus, the gp120-binding site of CD4 is not limited to the CDR2-like sequence and consists of several discontinuous segments. Several amino acids were identified that are critical for the conformation of V1; the importance of these residues suggests some differences in the folding of this domain compared to immunoglobulin variable domains. Three amino acid substitutions were found that increase the affinity for gp120 significantly (1.7- to 2-fold individually and 4.2-fold when combined), suggesting that it may be possible to improve the HIV-blocking ability of CD4-based molecules by increasing their gp120 binding affinity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402498      PMCID: PMC54701          DOI: 10.1073/pnas.87.18.7150

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  CD4: collaborator in immune recognition and HIV infection.

Authors:  E Robey; R Axel
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

2.  Analysis of the site in CD4 that binds to the HIV envelope glycoprotein.

Authors:  M H Brodsky; M Warton; R M Myers; D R Littman
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

3.  Identification of the residues in human CD4 critical for the binding of HIV.

Authors:  J Arthos; K C Deen; M A Chaikin; J A Fornwald; G Sathe; Q J Sattentau; P R Clapham; R A Weiss; J S McDougal; C Pietropaolo
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

4.  Designing CD4 immunoadhesins for AIDS therapy.

Authors:  D J Capon; S M Chamow; J Mordenti; S A Marsters; T Gregory; H Mitsuya; R A Byrn; C Lucas; F M Wurm; J E Groopman
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

5.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis.

Authors:  B C Cunningham; J A Wells
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

6.  A predicted three-dimensional structure for the human immunodeficiency virus binding domains of CD4 antigen.

Authors:  P A Bates; M J McGregor; S A Islam; Q J Sattentau; M J Sternberg
Journal:  Protein Eng       Date:  1989-10

7.  CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.

Authors:  P L Nara; K M Hwang; D M Rausch; J D Lifson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

8.  The MHC-binding and gp120-binding functions of CD4 are separable.

Authors:  D Lamarre; A Ashkenazi; S Fleury; D H Smith; R P Sekaly; D J Capon
Journal:  Science       Date:  1989-08-18       Impact factor: 47.728

9.  A 113-amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion.

Authors:  B H Chao; D S Costopoulos; T Curiel; J M Bertonis; P Chisholm; C Williams; R T Schooley; J J Rosa; R A Fisher; J M Maraganore
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

10.  Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes.

Authors:  Q J Sattentau; J Arthos; K Deen; N Hanna; D Healey; P C Beverley; R Sweet; A Truneh
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  53 in total

1.  Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding.

Authors:  E C Hsu; R E Dörig; F Sarangi; A Marcil; C Iorio; C D Richardson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Crystal structure of an HIV-binding recombinant fragment of human CD4.

Authors:  S E Ryu; P D Kwong; A Truneh; T G Porter; J Arthos; M Rosenberg; X P Dai; N H Xuong; R Axel; R W Sweet
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

3.  Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.

Authors:  C Vita; E Drakopoulou; J Vizzavona; S Rochette; L Martin; A Ménez; C Roumestand; Y S Yang; L Ylisastigui; A Benjouad; J C Gluckman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

4.  Mutations in the D strand of the human CD4 V1 domain affect CD4 interactions with the human immunodeficiency virus envelope glycoprotein gp120 and HLA class II antigens similarly.

Authors:  D Piatier-Tonneau; L N Gastinel; G Moussy; B Bénichou; F Amblard; P Vaigot; C Auffray
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

5.  Reduced monomeric CD4 is the preferred receptor for HIV.

Authors:  Lisa J Matthias; Iman Azimi; Catherine A Tabrett; Philip J Hogg
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

6.  Construction of a binding site for human immunodeficiency virus type 1 gp120 in rat CD4.

Authors:  G A Schockmel; C Somoza; S J Davis; A F Williams; D Healey
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

7.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

8.  Identification of a ligand-binding site in an immunoglobulin fold domain of the Saccharomyces cerevisiae adhesion protein alpha-agglutinin.

Authors:  H de Nobel; P N Lipke; J Kurjan
Journal:  Mol Biol Cell       Date:  1996-01       Impact factor: 4.138

9.  A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1.

Authors:  J P Moore
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Design and synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes.

Authors:  S Chen; R A Chrusciel; H Nakanishi; A Raktabutr; M E Johnson; A Sato; D Weiner; J Hoxie; H U Saragovi; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.